This study develops a replication competent reporter IAV by fusing an 11-amino acid HiBiT tag into the nonstructural protein 1 (NS1) of the A/WSN/1933 (H1N1) backbone and identifies CIM53 as a potential host-directed adjunct therapy for severe IAV Infection.
Abstract
Influenza A virus (IAV) remains a major threat to human and animal health, highlighting the need for efficient approaches to identify host factors and antivirals. Reporter viruses are critical tools for these efforts, but incorporating large reporter genes often compromises viral fitness and genetic stability. Here, we developed a replication competent reporter IAV by fusing an 11-amino acid HiBiT tag into the nonstructural protein 1 (NS1) of the A/WSN/1933 (H1N1) backbone. The modified virus retained parental virion morphology, comparable replication kinetics, and in vivo tissue tropism, while enabling the highly sensitive, rapid, and quantitative detection of viral replication. Using this reporter virus, we established a robust high-throughput screening (HTS) platform with excellent assay quality and validated its capability to identify host regulators of IAV infection. Application of this platform to host-encoded micropeptides (miPEPs) led to the identification of cytokine-inhibitory micropeptide 53 (CIM53) as a novel regulator of IAV replication. Mechanistically, CIM53 promoted IAV replication by intrinsically suppressing antiviral innate immune responses. Furthermore, although CIM53 enhanced viral replication, its immunomodulatory activity contributed to reduced lung injury and improved survival when combined with Oseltamivir (OSV) treatment in infected mice. Our study establishes a highly practical screening platform for virological research and highlights CIM53 as a potential host-directed adjunct therapy for severe IAV Infection.
ABSTRACT Reporter-expressing recombinant influenza A viruses (IAVs) have emerged as powerful tools for studying viral infection, host–pathogen interactions, and the identification and characterization of prophylactic and/or therapeutic countermeasures for the treatment of IAV infections. By incorporating a reporter gen...
Ramya S. Barre, H. Nath, A. Nogales et al.· Journal of Virology· 0 citations
By systematically removing host restriction factors, this platform provides a versatile and powerful strategy for accelerating viral propagation, offering a strong foundation for more efficient development and large-scale production of cell culture-based anti-viral vaccines.
Zheng-Mei Xu, Jaemyeong Jeon, Jinsoo Oh et al.· Frontiers in Bioengineering...· 0 citations
This study is the first to identify circ-INSR as a host factor contributing to influenza virus replication, and provides a basis for developing circRNA-based strategies against H9N2 avian influenza virus.
ABSTRACT Climate change has expanded the range of vectors for the chikungunya virus (CHIKV), thereby increasing its global threat. This situation underscores the urgent need for antiviral therapies. However, the development of drugs is limited by the need for Biosafety Level 3 (BSL-3) containment and the lack of tools...
Mengyuan Zheng, Zhouling Pan, Yanxiang Jiang et al.· Journal of Virology· 0 citations
Abstract Usutu virus (USUV) is an emerging mosquito-borne orthoflavivirus closely related to West Nile and Japanese encephalitis viruses. Despite its increasing prevalence in Europe and reports of neuroinvasive disease in humans, the molecular and immunological determinants of USUV infection remain poorly understood, l...
Amy N. Nelson, Aaron E. Lin, Saloni Sinha et al.· PNAS Nexus· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.